Avalanche Biotechnologies Gives Ocular BioFactory Tour

Thomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform, Ocular BioFactory. Avalanche’s lead product, AVA-101, is undergoing Phase IIa clinical trials for wet AMD; the company could submit an investigational new drug applications in the second half of 2015. Avalanche is testing the compound against diabetic macular edema (DME) and retinal vein occlusions as well. It also has entered into a partnership with Regeneron to pursue multiple applications of its AVA-311 preclinical product.


Thomas W. Chalberg, PhD

Thomas W. Chalberg, PhD

Dr. Chalberg is a Co-Founder and CEO of Avalanche. He has helped the company advance by recruiting the management team and scientific advisory board, and by leading business development efforts related to in-licensing and research collaborations.

View Full Profile